Pembrolizumab Combo May Benefit Elderly Metastatic NSCLC Cohort
Results showed one complete response to therapy and 17 partial responses in patients. Findings from a phase 2 trial published in JTO Clinical and Research Reports suggest that pembrolizumab (Keytruda) plus pemetrexed may be a promising frontline option for older patients with metastatic nonsquamous NSCLC and a PD-L1 tumor proportion score (TPS) below 50%.1 After … Read more